Orion Corporation
https://www.orion.fi/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Orion Corporation
In Times Of Adversity, Surgical Robot Developers Must Remain Sharp
Harsh economic conditions and increased competition are dictating that surgical robotics companies must quickly adopt new commercial strategies. In Vivo speaks to key players in the space to learn more.
Finance Watch: Novartis Sets October Separation Date For Sandoz Spin-Off
Novartis revealed detailed terms and a 4 October spin-off date for Sandoz’s standalone debut. Also, MIRA launched a small IPO, but two firms plan to go public in SPAC mergers. Also, Mirati’s $345m offering leads follow-ons offerings and Sangon Biotech raised $290m in venture capital.
Marinus On Track To Be Leader In Rare Epilepsy Market, Says CEO
CEO Scott Braunstein, who took leadership of Marinus in 2019 following clinical trial setbacks, believes the company is on a route to success with its ganaxolone program, targeting chronic use and hospital markets.
Asia Deal Watch: Astellas Expands Protein Degrader R&D Capability With PeptiDream Collaboration
Plus deals involving Santen/Harrow/Visiox, Aurobindo/BioFactura, AFT/Crossject, Imugene/RenovoRx, Biotheus/BioNTech, GeneQuantum/InxMed, ObsEva/Yuyuan, Monopar/National University of Singapore and Doer Biologics/BioNTech.
Company Information
- Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Vaccines
-
Drug Delivery
- Pulmonary
- Other Names / Subsidiaries
-
- Orion Corporation
- Orion Diagnostica Oy
- Orion Pharma
- Orion Oyj
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice